Romosozumab and Teriparatide Effects on Lumbar Spine and Hip Volumetric Bone Mineral Density and Content.

Trial Profile

Romosozumab and Teriparatide Effects on Lumbar Spine and Hip Volumetric Bone Mineral Density and Content.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2014

At a glance

  • Drugs Romosozumab (Primary) ; Teriparatide
  • Indications Osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Amgen
  • Most Recent Events

    • 08 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top